A Phase III, 4-week, Randomized, Double-blind Study to Compare 'Closed' Triple Therapy (FF/UMEC/VI), 'Open' Triple Therapy (FF/VI + UMEC) and Dual Therapy (FF/VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Trial Profile

A Phase III, 4-week, Randomized, Double-blind Study to Compare 'Closed' Triple Therapy (FF/UMEC/VI), 'Open' Triple Therapy (FF/VI + UMEC) and Dual Therapy (FF/VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 25 Jul 2016

At a glance

  • Drugs Fluticasone furoate/umeclidinium/vilanterol (Primary) ; Umeclidinium (Primary) ; Vilanterol/fluticasone furoate (Primary) ; Salbutamol
  • Indications Chronic obstructive pulmonary disease
  • Focus Registrational; Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 20 Jul 2016 Status changed from not yet recruiting to withdrawn prior to enrolment.
    • 16 Jun 2016 Planned End Date changed from 1 Oct 2016 to 1 Nov 2016.
    • 16 Jun 2016 Planned primary completion date changed from 1 Oct 2016 to 1 Nov 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top